About the journal
Cancer Pathogenesis and Therapy is an open-access journal published by Elsevier in Netherlands, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 2,700 USD. Declared review time at DOAJ: 48 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 2097-2563 · 2949-7132
- Country
- Netherlands
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,700 USD
- Articles in DOAJ
- 182
- Declared review time
- 48 weeks
- Declared peer-review model
- peer_review
Index listings
- DOAJ · 2023-07-18
- Indexing
- DOAJ
- APC
- 2,700 USD
- Declared review time (DOAJ)
- 48 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
182
Most recent article
3 months ago
Average review time (journal-declared via DOAJ)
48weeks
Works in OpenAlex
222
Last recorded publication year
2026
h-index
19
i10-index
38
From OpenAlex open data (CC0).
Editorial & policy11
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2023-07-18
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 82%
- ORCID iDs in current deposits
- 68%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 9918680788606676
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Ferroelectric and Negative Capacitance Devices
- Big Data and Digital Economy
Show all subjects (50)
- Big Data and Digital Economy
- Ferroelectric and Negative Capacitance Devices
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
- Acute Myeloid Leukemia Research
- Immune cells in cancer
- Lung Cancer Research Studies
- Acute Myeloid Leukemia Research
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Immune cells in cancer
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- MicroRNA in disease regulation
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Multiple Myeloma Research and Treatments
- Circular RNAs in diseases
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Circular RNAs in diseases
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Glioma Diagnosis and Treatment
- Human auditory perception and evaluation
- Human auditory perception and evaluation
- Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Breast Cancer Treatment Studies
- Acute Lymphoblastic Leukemia research
Keywords (DOAJ)
- oncological pharmacology
- cancer genomics
- cancer informatics
- oncology
- cancer prevention
- cancer research
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ